- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03893955
A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-927 With ABBV-368, Budigalimab (ABBV-181) and/or Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors
February 3, 2023 updated by: AbbVie
A Phase 1, Multicenter, Open-Label Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Combinations of ABBV-927 With ABBV-368, Budigalimab (ABBV-181) and/or Chemotherapy in Subjects With Locally Advanced or Metastatic Solid Tumors
A study evaluating the safety, pharmacokinetics (PK), pharmacodynamics, and preliminary efficacy of ABBV-927 with ABBV-368, Budigalimab (ABBV-181) and/or chemotherapy in participants with selected solid tumors.
This study consists of 2 main parts, a dose-escalation phase and a dose-expansion phase.
The dose-expansion phase can begin once the recommended phase 2 dose/maximum tolerated dose (RP2D/MTD) is determined in the dose-escalation phase.
Study Overview
Status
Active, not recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
150
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Queensland
-
South Brisbane, Queensland, Australia, 4101
- Icon Cancer Centre /ID# 224084
-
-
-
-
-
Clermont Ferrand, France, 63011
- Centre Jean Perrin /ID# 217911
-
Paris, France, 75018
- AP-HP - Hopital Bichat - Claude-Bernard /ID# 212869
-
-
Ile-de-France
-
Paris CEDEX 05, Ile-de-France, France, 75248
- Institut Curie /ID# 223475
-
-
Loire-Atlantique
-
St Herblain CEDEX, Loire-Atlantique, France, 44805
- Institut de Cancérologie de l'Ouest René Gauducheau /ID# 212880
-
-
Rhone
-
Lyon CEDEX 08, Rhone, France, 69373
- Centre Leon Berard /ID# 217910
-
-
-
-
Tel-Aviv
-
Ramat Gan, Tel-Aviv, Israel, 5265601
- The Chaim Sheba Medical Center /ID# 211699
-
-
-
-
-
Barcelona, Spain, 08035
- Hospital Universitario Vall d'Hebron /ID# 212804
-
Madrid, Spain, 28040
- Hospital Universitario Fundacion Jimenez Diaz /ID# 212806
-
Madrid, Spain, 28050
- Hospital Universitario HM Sanchinarro /ID# 212805
-
Malaga, Spain, 29010
- Hospital Universitario Virgen de la Victoria /ID# 221671
-
-
-
-
-
Taichung City, Taiwan, 40447
- China Medical University Hospital /ID# 221090
-
Taipei City, Taiwan, 100
- National Taiwan University Hospital /ID# 210993
-
-
-
-
Arkansas
-
Springdale, Arkansas, United States, 72762
- Highlands Oncology Group, PA /ID# 218863
-
-
California
-
Santa Rosa, California, United States, 95403
- St Jude Hospital dba St Joseph /ID# 211130
-
-
Connecticut
-
New Haven, Connecticut, United States, 06510
- Yale University /ID# 210678
-
-
Florida
-
Tampa, Florida, United States, 33612-9416
- Moffitt Cancer Center /ID# 215037
-
-
Indiana
-
Fort Wayne, Indiana, United States, 46804
- Fort Wayne Medical Oncology and Hematology, Inc /ID# 226072
-
-
Missouri
-
Saint Louis, Missouri, United States, 63110
- Washington University-School of Medicine /ID# 221399
-
-
North Carolina
-
Durham, North Carolina, United States, 27710-3000
- Duke Cancer Center /ID# 217641
-
Huntersville, North Carolina, United States, 28078
- Carolina BioOncology Institute /ID# 210664
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, United States, 15232
- UPMC Hillman Cancer Ctr /ID# 222747
-
-
Tennessee
-
Nashville, Tennessee, United States, 37203-1632
- Tennessee Oncology-Nashville Centennial /ID# 221400
-
-
Texas
-
Dallas, Texas, United States, 75230
- Mary Crowley Cancer Research /ID# 210716
-
San Antonio, Texas, United States, 78229
- NEXT Oncology /ID# 210717
-
-
Virginia
-
Fairfax, Virginia, United States, 22031
- Virginia Cancer Specialists - Fairfax /ID# 210671
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Adequate liver, kidney and hematology function as demonstrated by laboratory values detailed in the study protocol.
- An Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
Dose-Escalation:
- Arm A: Participants with an advanced solid tumor who have progressed on standard therapies known to provide clinical benefit and/or participants who have refused or are intolerant of such therapy.
- Arm B (non-small-cell-lung-cancer [NSCLC]): Participants with histologically or cytologically confirmed NSCLC who previously progressed during or after an anti-programmed cell death (PD)-1 or PD ligand 1 (PD-L1) therapy and a platinum-based regimen in the recurrent or metastatic setting.
Dose-Expansion:
- Arm 1, 2, and 3 (triple-negative breast cancer [TNBC]): Participants with histologically or cytologically confirmed breast adenocarcinoma that is estrogen receptor/progesterone receptor/human epidermal growth factor receptor (HER)2-negative who must have disease progression during or after at least 1 systemic therapy that included a taxane in the metastatic or recurrent setting and who are treatment-naïve to immunotherapy.
- Arm 4 (TNBC): Participants with histologically or cytologically confirmed TNBC who have received no previous anti-cancer therapy for TNBC, and who are PD-L1 negative on tumor tissue by immunohistochemistry (IHC) assay.
- Arm 5 (NSCLC): Participants with histologically or cytologically confirmed NSCLC who previously progressed either during or after an anti-PD-1 or PD-L1 therapy and a platinum-based regimen in the recurrent or metastatic setting.
Exclusion Criteria:
- Has history of inflammatory bowel disease or pneumonitis.
- Has uncontrolled metastases to the central nervous system.
- Has a concurrent malignancy that is clinically significant, treatment is required, or the participant is not clinically stable.
- Has had a major surgery ≤ 28 days prior to the first dose of study drug or the surgical wound is not fully healed.
- Has previously treated with an anti-PD- or PD-L1-targeting agent and had during the course of their therapy:
- any immune-mediated toxicity of Grade 3 or worse severity
- treatment of the toxicity with systemic corticosteroids
- any hypersensitivity to the PD-1 or PD-L1-targeting agent
- any treatment-related toxicity resulting in discontinuation of the PD-1 or PD-L1 targeting agent
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NON_RANDOMIZED
- Interventional Model: SEQUENTIAL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Dose Escalation Arm A: ABBV-927 + ABBV-368 Solid Tumors
Participants with Solid Tumors will receive various doses of ABBV-927 by intravenous (IV) infusion plus ABBV-368.
This will determine the recommended phase two dose (RP2D) of ABBV-927.
|
Intravenous (IV) Infusion
Intravenous (IV) Infusion
|
EXPERIMENTAL: Dose Escalation Arm B: ABBV-927 + ABBV-368 + ABBV-181 NSCLC
Participants with non-small-cell-lung-cancer (NSCLC) will receive ABBV-927 IV at various dose levels + ABBV-368 + ABBV-181.
This will determine the recommended phase two dose (RP2D) of ABBV-927 + ABBV-368 + ABBV-181.
|
Intravenous (IV) Infusion
Other Names:
Intravenous (IV) Infusion
Intravenous (IV) Infusion
|
EXPERIMENTAL: Dose Expansion Arm 1: ABBV-927 + Carboplatin + ABBV-368 TNBC
Participants with Triple Negative Breast Cancer (TNBC) will receive ABBV-927 (at the RP2D established in Arm A) + Carboplatin + ABBV-368 by IV.
|
Intravenous (IV) Infusion
Intravenous (IV) Infusion
Intravenous (IV) Infusion
|
EXPERIMENTAL: Dose Expansion Arm 2: ABBV-927 + Carboplatin + ABBV-181 TNBC
Participants with TNBC will receive ABBV-927 (at the RP2D established in Arm A) + Carboplatin + ABBV-181 by IV.
|
Intravenous (IV) Infusion
Other Names:
Intravenous (IV) Infusion
Intravenous (IV) Infusion
|
EXPERIMENTAL: Dose Expansion Arm 3: ABBV-927 + Carboplatin TNBC
Participants with TNBC will receive ABBV-927 (at the RP2D established in Arm A) + Carboplatin by IV.
|
Intravenous (IV) Infusion
Intravenous (IV) Infusion
|
EXPERIMENTAL: Dose Expansion Arm 4: ABBV-927+ Nab-paclitaxel + ABBV-368 TNBC
Participants with TNBC will receive ABBV-927 (at the RP2D established in Arm A) + Nab-paclitaxel + ABBV-368 by IV.
|
Intravenous (IV) Infusion
Intravenous (IV) Infusion
Intravenous (IV) Infusion
|
EXPERIMENTAL: Dose Expansion Arm 5: ABBV-927 + ABBV-368 + ABBV-181 NSCLC
Participants with NSCLC will receive ABBV-927 (at the RP2D established in Arm B) + ABBV-368 + ABBV-181 by IV.
|
Intravenous (IV) Infusion
Other Names:
Intravenous (IV) Infusion
Intravenous (IV) Infusion
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Dose Expansion: Objective Response Rate (ORR)
Time Frame: Up to approximately 2 years following the first dose of study drug
|
ORR is defined as the percentage of participants with either complete response (CR) or partial response (PR) based on Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.
|
Up to approximately 2 years following the first dose of study drug
|
Dose-Escalation Phase: Recommended Phase 2 Dose (RP2D) of ABBV-927 + ABBV-368
Time Frame: Up to approximately 6 months
|
The RP2D of ABBV-927 + ABBV-368 will be determined during the dose-escalation phase of the study.
RP2D will be determined using available safety and pharmacokinetics data.
|
Up to approximately 6 months
|
Dose-Escalation Phase: Recommended Phase 2 Dose (RP2D) of ABBV-927 + ABBV-368 + ABBV-181
Time Frame: Up to approximately 6 months
|
The RP2D of ABBV-927 + ABBV-368 + ABBV-181 will be determined during the dose-escalation phase of the study.
RP2D will be determined using available safety and pharmacokinetics data.
|
Up to approximately 6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Dose-Expansion Phase: Progression-free Survival (PFS)
Time Frame: Up to approximately 2 years since the first dose of study drug
|
PFS is defined as the time from date of first study drug exposure to disease progression or death, whichever occurs first.
|
Up to approximately 2 years since the first dose of study drug
|
Dose-Expansion Phase: Duration of Response (DOR)
Time Frame: Up to approximately 2 years since the first dose of study drug
|
DOR defined as the time from the participant's initial response to study drug therapy to disease progression or death, whichever occurs first.
|
Up to approximately 2 years since the first dose of study drug
|
Maximum Serum Concentration (Cmax)
Time Frame: Up to approximately 12 weeks after participant's initial dose of study drug
|
Maximum Serum Concentration (Cmax)
|
Up to approximately 12 weeks after participant's initial dose of study drug
|
Time to Maximum Observed Serum Concentration (Tmax)
Time Frame: Up to approximately 12 weeks after participant's initial dose of study drug
|
Time to Maximum Observed Serum Concentration (Tmax)
|
Up to approximately 12 weeks after participant's initial dose of study drug
|
Area Under the Serum Concentration Versus Time Curve from Time 0 to the Time of the Last Measurable Concentration (AUCτ)
Time Frame: Up to approximately 12 weeks after participant's initial dose of study drug
|
Area under the serum concentration versus time curve from time 0 to the time of the last measurable concentration (AUCτ).
|
Up to approximately 12 weeks after participant's initial dose of study drug
|
Terminal Phase Elimination Half-life (t1/2)
Time Frame: Up to approximately 4 weeks after participant's initial dose of study drug
|
Terminal Phase Elimination Half-life (t1/2)
|
Up to approximately 4 weeks after participant's initial dose of study drug
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
May 21, 2019
Primary Completion (ANTICIPATED)
November 12, 2023
Study Completion (ANTICIPATED)
November 12, 2023
Study Registration Dates
First Submitted
March 27, 2019
First Submitted That Met QC Criteria
March 27, 2019
First Posted (ACTUAL)
March 28, 2019
Study Record Updates
Last Update Posted (ACTUAL)
February 6, 2023
Last Update Submitted That Met QC Criteria
February 3, 2023
Last Verified
February 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Skin Diseases
- Respiratory Tract Diseases
- Lung Diseases
- Neoplasms by Site
- Breast Diseases
- Respiratory Tract Neoplasms
- Thoracic Neoplasms
- Carcinoma, Bronchogenic
- Bronchial Neoplasms
- Lung Neoplasms
- Breast Neoplasms
- Neoplasms
- Carcinoma, Non-Small-Cell Lung
- Triple Negative Breast Neoplasms
- Molecular Mechanisms of Pharmacological Action
- Antineoplastic Agents
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Antineoplastic Agents, Phytogenic
- Carboplatin
- Paclitaxel
Other Study ID Numbers
- M19-037
- 2019-000478-45 (EUDRACT_NUMBER)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cancer
-
University of Michigan Rogel Cancer CenterRecruitingCancer Liver | Cancer Brain | Cancer Head &Neck | Cancer PelvisUnited States
-
Cellworks Group Inc.RecruitingCancer | Relapsed Cancer | Refractory CancerUnited States
-
UNC Lineberger Comprehensive Cancer CenterHyundai Hope On WheelsRecruitingCancer | Pediatric Cancer | Survivorship | Cancer MetastaticUnited States
-
Vanderbilt-Ingram Cancer CenterNational Institutes of Health (NIH)Active, not recruitingAdvanced Cancer | Relapsed Cancer | Refractory CancerUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)CompletedStage III Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IV Gastric Cancer | Stage IVA Colorectal Cancer | Stage IVA Pancreatic Cancer | Stage IVB Colorectal Cancer | Stage IVB Pancreatic Cancer | Stage IIIA Gastric Cancer | Stage IIIB Gastric Cancer | Stage IIIC Gastric... and other conditionsUnited States
-
MiRXES Pte LtdRecruitingBreast Cancer | Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Esophageal Cancer | Ovarian Cancer | Prostate Cancer | Thoracic Cancer | Liver CancerSingapore
-
Sidney Kimmel Cancer Center at Thomas Jefferson...CompletedStage I Breast Cancer | Stage I Uterine Corpus Cancer | Stage II Uterine Corpus Cancer | Stage III Uterine Corpus Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage... and other conditionsUnited States
-
Massachusetts General HospitalNational Comprehensive Cancer NetworkCompletedGastric Cancer | Pancreatic Cancer | Esophageal Cancer | Rectal Cancer | Colon Cancer | Hepatobiliary CancerUnited States
-
University of California, San FranciscoBristol-Myers Squibb; PfizerTerminatedStage IIIA Rectal Cancer | Stage IIIB Rectal Cancer | Stage IIIC Rectal Cancer | Metastatic Colorectal Adenocarcinoma | Metastatic Colon Adenocarcinoma | Metastatic Rectal Adenocarcinoma | Stage IIIA Colon Cancer | Stage IIIB Colon Cancer | Stage IIIC Colon Cancer | Stage IV Colon Cancer | Stage IV Rectal... and other conditionsUnited States
-
Johns Hopkins UniversityNational Cancer Institute (NCI); National Institute on Minority Health and...Enrolling by invitationCancer | Advanced Cancer | End Stage Cancer | MalignancyUnited States
Clinical Trials on ABBV-181
-
AbbVieCompletedAdvanced Solid Tumors CancerUnited States, France, Japan, Puerto Rico, Spain, Taiwan
-
AbbVieTerminated
-
AbbVieRecruiting
-
AbbVieCompletedSmall Cell Lung CancerUnited States, Japan, Korea, Republic of, Taiwan
-
AbbVieCompletedHuman Immunodeficiency Virus (HIV)United States, Puerto Rico
-
AbbVieTerminated
-
AbbVieActive, not recruitingAdvanced Solid Tumors CancerUnited States, Australia, Canada, France, Japan, Korea, Republic of, Spain
-
AbbVieTerminatedColorectal CancerUnited States
-
AbbVieRecruitingAdvanced Solid Tumors CancerUnited States, Australia, Belgium, Israel, Japan, Korea, Republic of, Puerto Rico, Spain, Taiwan, Canada, France
-
AbbVieCompletedHIV Infection | HIV-1 | Human Immunodeficiency Virus (HIV)United States, Australia, Canada, Puerto Rico